Organic Active Ingredients TRIZ Cases

Targeting the mTOR signaling pathway with inhibitors reduces plantar hyperkeratosis and pain scores in pachyonychia congenita patients.

Targeted alphaVbeta6 inhibitors block TGF-beta1 activation to improve lung function while reducing side effects from broad antifibrotic therapies.

A fibrous composite material uses electrospun polymeric fibers to form a porous scaffold for synthetic amniotic membrane applications.

Targeting CDK9 and BRD4 transcriptional elongation reduces cartilage degradation and prevents systemic inflammatory response syndrome onset.

Converting the active compound into succinate or napadisylate salts resolves manufacturing difficulties caused by unpredictable physical characteristics.

Continuous inert gas sparging removes dissolved oxygen from epinephrine formulations, preventing oxidative degradant formation and extending shelf life.

Anti-OX40L antibodies block OX40L signaling to decrease TNF-alpha and leukocyte proliferation in inflammatory diseases.

Stable pyrido[3,4-d]pyrimidine crystals resolve chemical stability issues while maintaining high CDK4/6 inhibitory activity.

Chitosan enhances nalbuphine absorption through the nasal mucosa, resolving low bioavailability in non-invasive pain relief.

Drug-resin particles with immediate and delayed release coatings provide prolonged amphetamine therapy, reducing administration frequency for children.

Charged lipid compositions protect nucleic acids from nuclease digestion, extending half-life and reducing systemic toxicity.

Neutral human milk oligosaccharides stimulate Bifidobacterium proliferation to inhibit pathogenic infections despite delayed abundance increases.

Astarabine prodrugs link cytarabine to amino acids, enabling higher doses with reduced toxicity in hematological cancer treatment.

Drink formulation with shear banding properties forms a stationary layer to moderate blood glucose levels, resolving interference with medication kinetics.

A pharmaceutical composition incorporating triglycerides and hydroxypropylcellulose to form complexes that interfere with drug crystallization.

Pyrrolo[2,3-d]pyrimidine derivative evades p-gp efflux to enhance brain penetration while maintaining potent HER2 inhibition.

A multi-layer polymer coating provides a positive zeta-potential, enabling efficient drug transfer from balloon catheters to dynamic surfaces.

MAT2A inhibitors disrupt SAM production in MTAP-deleted cancers, addressing limited treatment options by selectively targeting metabolic vulnerabilities.

Administering naltrexone and bupropion reduces major adverse cardiovascular events while managing disease progression in obese patients.

Modified kinase compounds overcome multi-drug resistance by altering molecular parameters to improve treatment effectiveness for hyperproliferative disorders.

Selective COX-2 inhibition reduces gastrointestinal toxicities while crystalline forms A or G maintain physicochemical stability.

Segmented fused pyridine structures overcome limited inhibitor variety to treat circadian disorders.

Liposomal encapsulation protects thrombin from auto-proteolysis, resolving the trade-off between two-component complexity and single-component stability.

Oxazole compounds antagonize orexin receptors, addressing limited efficacy and specificity in treating neurological disorders.

Single stranded oligonucleotides bind PRC2-associated regions to relieve repression and increase functional SMN protein for spinal muscular atrophy treatment.

Detecting MUC4 gene polymorphisms identifies patients at risk of diffuse alveolar damage before anticancer drug administration.

Lipid nanoparticles with lysophosphatidylcholine hyperactivate dendritic cells, increasing IL-1β secretion and long-lived T cell responses.

Single-stranded circular polynucleotides use nucleoside modifications to enhance structural integrity and protein expression rates.

A synthetic peptide-polymer system anchors hyaluronic acid to cartilage surfaces via non-covalent binding.

Novel imidazopyridine derivative inhibits cancer-related kinases including Src and Fyn enzymes.

A biodegradable poly(ester-anhydride) copolymer matrix enables sustained local release of antibiotics at the injection site.

Topical rifampicin ointment reduces hypertrophic scars and acne size by inhibiting neovascularization, avoiding skin thinning from invasive procedures.

Specific aryl substituents reduce brain penetration to minimize central nervous system side effects.

A composite extrudable solid of hydroxypropylmethylcellulose acetate succinate and isomalt reduces melt viscosity during processing.

TEM8 antibodies combined with microtubule inhibitors suppress tumor growth while sparing healthy vasculature from toxicity.

Combining anti-PD-1/VEGFA bispecific antibody with PARP inhibitor addresses insufficient immune activation and angiogenesis inhibition in cancer therapy.

PDGFRA inhibitors disrupt signaling to upregulate NIS and TTF1, restoring radioiodine uptake in papillary thyroid carcinoma resistant to standard therapy.

A crosslinked silyl-containing telechelic polyurea polymer provides strong skin adhesion and drug reservoir functions.

Neutralizing IL-17 cytokines with specific antibodies to reduce inflammatory responses triggered by metal implant debris.

Spirolactam derivatives provide controlled allosteric modulation of the mGlu5 receptor, preventing desensitization and enhancing selectivity.

Phenylimidazole compound targets PDE10A to reverse hyperactivity while minimizing extrapyramidal side effects.

Quinazoline derivatives block epidermal growth factor receptor activity to treat cancers linked to receptor overexpression.

Recombinant nucleic acid sequences encode synthetic antibodies targeting immune checkpoints to overcome weak antigen responses and enhance CD8+ T cell activity.

Membrane permeable creatine prodrugs bypass blood-brain barrier limitations to rapidly replenish ATP levels and protect tissues from ischemic stress.

Pyrazolo[1,5-a]pyrimidine derivatives selectively inhibit JAK1 and JAK3 kinases while avoiding off-target JAK2 activity.